Bone Ingrowth, Pain
Conditions
Keywords
Celebrex, Bone Ingrowth, Pain relief
Brief summary
The purpose of this study is to evaluate the effect of Celebrex on bone growth into porous coated implants, following postoperative total knee arthroplasty administration of Celebrex for pain relief.
Interventions
DRUGCelecoxib
Twelve hours prior to their first total knee surgery, patients will need to take an oral dose of Celebrex, 1 pill of 200mg. Following the patient's first total knee surgery, they will continue taking oral doses of Celebrex, 1 pill of 200 mg every twenty-four hours (200mg/day) for a two-week period.
Sponsors
Pfizer
University of Utah
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to 95 Years
Healthy volunteers
Yes
Inclusion criteria
* Male VA bilateral TKA patients 18 years or older with primary OA diagnosis
Exclusion criteria
* Patients with osteoporosis, hypersensitivity to Celebrex, allergy to tetracycline, Sulfonamides, patient with asthma, urticaria, or allergic-type reactions to aspirin or NSAIDs. * Patients who have had CABG. * Patients with a history of peptic ulcer disease, duodenal ulcers. * Female patients and patients diagnosed with unstable hypertension or hypotensive, with serum creative levels above 1.8-2.0 or diagnosed with severe renal disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bone Ingrowth | 12 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Pain Score | 10 days postoperative |
Countries
United States
Outcome results
None listed